ENGAGE THERAPEUTICS
Engage Therapeutics is a biopharmaceutical company bringing innovative medicines to market. The Company’s lead investigational drug is Staccato® alprazolam, a small, easy-to-use hand-held drug-device combination product that leverages an FDA-approved delivery system with FDA-approved alprazolam for the cessation of active and acute epileptic seizures. Staccato alprazolam in a Phase 2a proof of concept study demonstrated reduction of seizure in a photosensitivity model. The product will proceed into an advanced clinical setting leveraging a 505(b)(2) regulatory pathway.
ENGAGE THERAPEUTICS
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2017-01-01
Address:
Summit, New Jersey, United States
Country:
United States
Website Url:
http://www.engagetherapeutics.com
Total Employee:
1+
Status:
Closed
Total Funding:
23.6 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail YouTube DigiCert SSL RapidSSL Media Temple Combell
Current Advisors List
Current Employees Featured
Founder
Investors List
Granite Point Capital
Granite Point Capital investment in Series A - Engage Therapeutics
Lumira Ventures
Lumira Ventures investment in Series A - Engage Therapeutics
Adage Capital Management
Adage Capital Management investment in Series A - Engage Therapeutics
LifeSci Venture Partners
LifeSci Venture Partners investment in Series A - Engage Therapeutics
TPG Biotech
TPG Biotech investment in Series A - Engage Therapeutics
Official Site Inspections
http://www.engagetherapeutics.com
- Host name: 217.19.237.54.static.hosted.by.combell.com
- IP address: 217.19.237.54
- Location: Brussels Belgium
- Latitude: 50.8336
- Longitude: 4.3337
- Timezone: Europe/Brussels
- Postal: 1060
More informations about "Engage Therapeutics"
Engage Therapeutics Company Profile 2024: Valuation, …
Engage Therapeutics General Information Description. Developer of a drug-device product designed for the immediate termination of an ongoing epileptic seizure. The company's investigational product that is a small hand-held …See details»
Engage Therapeutics Inc - Company Profile and News
Engage Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company discovers and develops anti-epileptic drugs and medicines for the treatment of …See details»
Engage Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Engage Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 3 news, and 1 literature, Drug:Alprazolam. Biomedical products. ... The statistics …See details»
UCB acquires Engage Therapeutics: Staccato [®] Alprazolam - A …
Brussels (Belgium) 05 June 2020 – 7:00 (CEST) - regulated information – inside information – UCB announced today the acquisition of Engage Therapeutics, Inc. (Summit, N.J. (U.S.)), a …See details»
Greg Mayes - President, CEO & Founder @ Engage …
Prior to founding Engage Therapeutics, Greg played an integral role in the growth of Advaxis Immunotherapies, a Princeton, N.J., based biotech company developing immuno-oncology therapies for patients with hard-to-treat cancers …See details»
Engage Therapeutics - Facebook
Engage Therapeutics. 274 likes. Engage Therapeutics is a pharmaceutical company dedicated exclusively to the epilepsy community. We aSee details»
Engage Therapeutics - VentureRadar
Engage Therapeutics is a biopharmaceutical company bringing innovative medicines to market. The Company's lead investigational drug is Staccatoâ„¢... ... Find out more about Engage …See details»
Union Chimique Belge acquires Engage Therapeutics - Crunchbase
Jun 5, 2020 Engage Therapeutics Engage Therapeutics is a clinical stage pharmaceutical company with a deep-seated passion in epilepsy. Acquiring Organization: Union Chimique …See details»
UCB Acquires Engage Therapeutics for $125M - World Pharma …
UCB announced the acquisition of Engage Therapeutics, Inc., a clinical-stage pharmaceutical company developing Staccato®Alprazolam for the rapid termination of an active epileptic …See details»
Engage Therapeutics Doses First Patient in Phase 2b Trial
May 3, 2018 About Engage Therapeutics, Inc. ... Peachtree BioResearch Solutions, Inc. is a Clinical Research Organization that specializes in providing clinical development services for …See details»
UCB acquires Engage Therapeutics for $125m - Pharmaceutical …
Jun 8, 2020 Belgian biopharmaceutical firm UCB has acquired US-based pharmaceutical company Engage Therapeutics for a cash consideration of $125m. The terms of the deal also …See details»
UCB buys epilepsy drug maker Engage Therapeutics for $125M up …
Jun 5, 2020 UCB SA acquired Engage Therapeutics Inc. for an up-front payment of $125 million in cash. Summit, N.J.-based Engage Therapeutics may receive up to $145 million in potential …See details»
UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A …
BRUSSELS, Belgium, June 5, 2020 /PRNewswire/ — UCB announced today the acquisition of Engage Therapeutics, Inc. (Summit, N.J. (U.S.)), a clinical-stage pharmaceutical company …See details»
Engage Therapeutics Announces $23 Million Series A ... - Business …
Sep 27, 2017 Company: Engage Therapeutics, Inc. Gregory T. Mayes, 215-696-9659 President and CEO [email protected] or Media Contact: JPA Health Communications …See details»
Press Release: UCB acquires Engage Therapeutics: Staccato …
Brussels (Belgium) 05 June 2020 – 7:00 (CEST) - regulated information – inside information – UCB announced today the acquisition of Engage Therapeutics, Inc. (Summit, N.J. (U.S.)), a …See details»
UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A …
Jun 5, 2020 About Engage Therapeutics Engage Therapeutics, Summit, N.J., now a wholly-owned subsidiary of UCB, is a clinical stage pharmaceutical company with a deep-seated …See details»
Engage Therapeutics bags $23M to trial epilepsy drug-device combo
Sep 27, 2017 Engage Therapeutics, which is developing an EpiPen-like rescue treatment for epileptic seizures, raised $23 million to bankroll a phase 2b clinical trial of its drug-device …See details»
First meeting of the International Health Regulations (2005) …
Aug 19, 2024 The Director-General of the World Health Organization (WHO), having concurred with the advice offered by the International Health Regulations (2005) (IHR or Regulations) …See details»
ENGAGE THERAPEUTICS DOSES FIRST PATIENT IN PHASE 2B …
May 16, 2022 SUMMIT, N.J. – May 3, 2018 – Engage Therapeutics, Inc., today announced dosing of the first patient in its multi-center, double-blind, randomized Phase 2b StATES (St …See details»
Engage Therapeutics Doses First Patient in Phase 2b Trial of …
May 6, 2018 Topline Data Expected H2-2019 Peachtree BioResearch Solutions to Execute Multi-Center Trial SUMMIT, N.J., May 03, 2018 (GLOBE NEWSWIRE) — Engage …See details»